Basic Information
| RNALocate ID: | RLID:11000659 |
| RNA Symbol: | hsa-miR-15a-5p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-15a-5p |
| RNA ID: | miRBase:MIMAT0000068 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23382797 |
| Tissue/Cell Line: | Brain tissue |
| Method: | Microarray |
| Description: | We performed miRNA expression analysis using a FlexMAP3D instrument by (Luminex Corporation, Austin, TX) and a manufacturer's assay for 312 miRNA (Table S1). Data are collected from Table S1. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001249 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001250 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01001251 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:01001252 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001253 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001254 | Nucleus | Colon adenocarcinoma cells | 20864815 |
| RLID:11000655 | Exosome | Serum | 18589210 |
| RLID:11000656 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
| RLID:11000657 | Exosome | Renal cancer cells | 21670082 |
| RLID:11000658 | Exosome | Breast milk | 22211110 |
| RLID:11000660 | Exosome | Plasma | 23663360 |
| RLID:11000661 | Exosome | Human mast cell line (HMC-1) | 24009880 |
| RLID:11000662 | Exosome | Plasma | 24130905 |
| RLID:11000663 | Exosome | Serum | 25349172 |
| RLID:11000664 | Microvesicle | Plasma | 23077538 |
| RLID:11000665 | Microvesicle | Seminal plasma | 23539611 |
| RLID:11000666 | Microvesicle | Hepatoma cells | 23771658 |
| RLID:11005565 | Exosome | Peripheral blood | 32785072 |
| RLID-D:11000007 | Exosome | Blood|B lymphoblastoid cells|Endothelial cells|Lymphoma tissue|Mast cells | |
| RLID-D:11000267 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-15a-5p | Splenic marginal zone lymphoma | MNDR-E-MI-18022 |
| MNDR | hsa-miR-15a-5p | Polycystic liver disease | MNDR-E-MI-18023 |
| MNDR | hsa-miR-15a-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-18024 |
| MNDR | hsa-miR-15a-5p | Peripheral arterial disease | MNDR-E-MI-18025 |
| MNDR | hsa-miR-15a-5p | Oral squamous cell carcinoma | MNDR-E-MI-18026 |
| MNDR | hsa-miR-15a-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-18027 |
| MNDR | hsa-miR-15a-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-18028 |
| MNDR | hsa-miR-15a-5p | Lymphoma | MNDR-E-MI-18029 |
| MNDR | hsa-miR-15a-5p | Lymphoma non-hodgkin | MNDR-E-MI-18030 |
| MNDR | hsa-miR-15a-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-18031 |
| MNDR | hsa-miR-15a-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-18032 |
| MNDR | hsa-miR-15a-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-18033 |
| MNDR | hsa-miR-15a-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-18034 |
| MNDR | hsa-miR-15a-5p | Her2-receptor positive breast cancer | MNDR-E-MI-18035 |
| MNDR | hsa-miR-15a-5p | Triple negative breast cancer | MNDR-E-MI-18036 |
| MNDR | hsa-miR-15a-5p | Acute promyelocytic leukemia | MNDR-E-MI-18037 |
| MNDR | hsa-miR-15a-5p | Breast cancer luminal | MNDR-E-MI-18038 |
| MNDR | hsa-miR-15a-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-18039 |
| MNDR | hsa-miR-15a-5p | Prostate cancer | MNDR-E-MI-18040 |
| MNDR | hsa-miR-15a-5p | B-cell chronic lymphocytic leukemia | MNDR-E-MI-18041 |
| MNDR | hsa-miR-15a-5p | Gastric cancer | MNDR-E-MI-18042 |
| MNDR | hsa-miR-15a-5p | Gastric lymphoma | MNDR-E-MI-18043 |
| MNDR | hsa-miR-15a-5p | Alzheimer disease | MNDR-E-MI-18044 |
| MNDR | hsa-miR-15a-5p | Intracranial aneurysm | MNDR-E-MI-18045 |
| MNDR | hsa-miR-15a-5p | Esophageal carcinoma | MNDR-E-MI-18046 |
| MNDR | hsa-miR-15a-5p | Dysautonomia familial | MNDR-E-MI-18047 |
| MNDR | hsa-miR-15a-5p | Seizures | MNDR-E-MI-18048 |
| MNDR | hsa-miR-15a-5p | Huntington disease | MNDR-E-MI-18049 |
| MNDR | hsa-miR-15a-5p | Chorea | MNDR-E-MI-18050 |
| MNDR | hsa-miR-15a-5p | Cardiovascular disease | MNDR-E-MI-18051 |
| MNDR | hsa-miR-15a-5p | Moyamoya disease | MNDR-E-MI-18052 |
| MNDR | hsa-miR-15a-5p | Lung cancer | MNDR-E-MI-18053 |
| MNDR | hsa-miR-15a-5p | Endometrial cancer | MNDR-E-MI-18054 |
| MNDR | hsa-miR-15a-5p | Fragile x syndrome | MNDR-E-MI-18055 |
| MNDR | hsa-miR-15a-5p | Parkinson disease | MNDR-E-MI-18056 |
| MNDR | hsa-miR-15a-5p | Basal-like breast cancer | MNDR-E-MI-18057 |
| MNDR | hsa-miR-15a-5p | Pituitary neoplasms | MNDR-E-MI-18058 |
| MNDR | hsa-miR-15a-5p | Pancreatic cancer | MNDR-E-MI-18059 |
| MNDR | hsa-miR-15a-5p | Malignant melanoma | MNDR-E-MI-18060 |
| MNDR | hsa-miR-15a-5p | Gaucher disease | MNDR-E-MI-18061 |
| MNDR | hsa-miR-15a-5p | Rectum adenocarcinoma | MNDR-E-MI-18062 |
| MNDR | hsa-miR-15a-5p | Nephroblastoma | MNDR-E-MI-18063 |
| MNDR | hsa-miR-15a-5p | Colon cancer | MNDR-E-MI-18064 |
| MNDR | hsa-miR-15a-5p | Colon adenocarcinoma | MNDR-E-MI-18065 |
| MNDR | hsa-miR-15a-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-18066 |
| MNDR | hsa-miR-15a-5p | Familial ovarian cancer | MNDR-E-MI-18067 |
| MNDR | hsa-miR-15a-5p | Prostate adenocarcinoma | MNDR-E-MI-18068 |
| MNDR | hsa-miR-15a-5p | Kidney cancer | MNDR-E-MI-18069 |
| MNDR | hsa-miR-15a-5p | Carcinoma ductal breast | MNDR-E-MI-18070 |
| MNDR | hsa-miR-15a-5p | Glioblastoma | MNDR-E-MI-18071 |
| MNDR | hsa-miR-15a-5p | Astrocytoma | MNDR-E-MI-18072 |
| MNDR | hsa-miR-15a-5p | Glioma | MNDR-E-MI-18073 |
| MNDR | hsa-miR-15a-5p | Chronic obstructive pulmonary disease | MNDR-E-MI-18074 |
| MNDR | hsa-miR-15a-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-18075 |
| MNDR | hsa-miR-15a-5p | Osteosarcoma | MNDR-E-MI-18076 |
| MNDR | hsa-miR-15a-5p | Liposarcoma | MNDR-E-MI-18077 |
| MNDR | hsa-miR-15a-5p | Infarction middle cerebral artery | MNDR-E-MI-18078 |
| MNDR | hsa-miR-15a-5p | Meningioma | MNDR-E-MI-18079 |
| MNDR | hsa-miR-15a-5p | Liver cancer | MNDR-E-MI-18080 |
| MNDR | hsa-miR-15a-5p | Gastric adenocarcinoma | MNDR-E-MI-18081 |
| MNDR | hsa-miR-15a-5p | Cervical squamous cell carcinoma | MNDR-E-MI-18082 |
| MNDR | hsa-miR-15a-5p | Pituitary adenoma | MNDR-E-MI-18083 |
| MNDR | hsa-miR-15a-5p | Lung squamous cell carcinoma | MNDR-E-MI-18084 |
| MNDR | hsa-miR-15a-5p | Carcinoma lung non-small-cell | MNDR-E-MI-18085 |
| MNDR | hsa-miR-15a-5p | Lung adenocarcinoma | MNDR-E-MI-18086 |
| MNDR | hsa-miR-15a-5p | Thyroid carcinoma | MNDR-E-MI-18087 |
| MNDR | hsa-miR-15a-5p | Papillary thyroid carcinoma | MNDR-E-MI-18088 |
| MNDR | hsa-miR-15a-5p | Ovarian carcinoma | MNDR-E-MI-18089 |
| MNDR | hsa-miR-15a-5p | Bladder urothelial carcinoma | MNDR-E-MI-18090 |
| MNDR | hsa-miR-15a-5p | Pancreatic adenocarcinoma | MNDR-E-MI-18091 |
| MNDR | hsa-miR-15a-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-18092 |
| MNDR | hsa-miR-15a-5p | Carcinoma renal cell | MNDR-E-MI-18093 |
| MNDR | hsa-miR-15a-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-18094 |
| MNDR | hsa-miR-15a-5p | Clear cell renal cell carcinoma | MNDR-E-MI-18095 |
| MNDR | hsa-miR-15a-5p | Large cell carcinoma | MNDR-E-MI-18096 |
| MNDR | hsa-miR-15a-5p | Cholangiocarcinoma | MNDR-E-MI-18097 |
| MNDR | hsa-miR-15a-5p | Esophageal cancer | MNDR-E-MI-18098 |
| MNDR | hsa-miR-15a-5p | Oncocytoma | MNDR-E-MI-18099 |
| MNDR | hsa-miR-15a-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-18100 |
| MNDR | hsa-miR-15a-5p | T acute lymphoblastic leukemia | MNDR-E-MI-18101 |
| MNDR | hsa-miR-15a-5p | Acute t cell leukemia | MNDR-E-MI-18102 |
| MNDR | hsa-miR-15a-5p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-18103 |
| MNDR | hsa-miR-15a-5p | Breast invasive carcinoma | MNDR-E-MI-18104 |
| MNDR | hsa-miR-15a-5p | Hepatocellular carcinoma | MNDR-E-MI-18105 |
| MNDR | hsa-miR-15a-5p | Familiar ovarian carcinoma | MNDR-E-MI-18106 |
| MNDR | hsa-miR-15a-5p | B-cell lymphoma | MNDR-E-MI-18107 |
| MNDR | hsa-miR-15a-5p | Rheumatoid arthritis | MNDR-E-MI-18108 |
| MNDR | hsa-miR-15a-5p | T-cell leukemia | MNDR-E-MI-18109 |
| MNDR | hsa-miR-15a-5p | Abdominal aortic aneurysm | MNDR-E-MI-18110 |
| MNDR | hsa-miR-15a-5p | Chronic myelogenous leukemia | MNDR-E-MI-18111 |
| MNDR | hsa-miR-15a-5p | Hodgkin lymphoma | MNDR-E-MI-18112 |
| MNDR | hsa-miR-15a-5p | Burkitt lymphoma | MNDR-E-MI-18113 |
| MNDR | hsa-miR-15a-5p | Myeloid leukemia | MNDR-E-MI-18114 |
| MNDR | hsa-miR-15a-5p | Neuromyelitis optica | MNDR-E-MI-18115 |
| MNDR | hsa-miR-15a-5p | Acute myelogenous leukemia | MNDR-E-MI-18116 |
| MNDR | hsa-miR-15a-5p | Colorectal cancer | MNDR-E-MI-18117 |
| MNDR | hsa-miR-15a-5p | Nasopharynx carcinoma | MNDR-E-MI-18118 |
| MNDR | hsa-miR-15a-5p | Tyrosinemias | MNDR-E-MI-18119 |
| MNDR | hsa-miR-15a-5p | Multiple myeloma | MNDR-E-MI-18120 |
| MNDR | hsa-miR-15a-5p | Acute lymphocytic leukemia | MNDR-E-MI-18121 |
| MNDR | hsa-miR-15a-5p | Ependymoma | MNDR-E-MI-18122 |
| MNDR | hsa-miR-15a-5p | Nasopharyngeal cancer | MNDR-E-MI-18123 |
| MNDR | hsa-miR-15a-5p | Cerebral hemorrhage traumatic | MNDR-E-MI-18124 |
| MNDR | hsa-miR-15a-5p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-18125 |
| MNDR | hsa-miR-15a-5p | Intracranial hemorrhage hypertensive | MNDR-E-MI-18126 |
| MNDR | hsa-miR-15a-5p | Pituitary acth hypersecretion | MNDR-E-MI-18127 |
| MNDR | hsa-miR-15a-5p | Stroke lacunar | MNDR-E-MI-18128 |
| MNDR | hsa-miR-15a-5p | Breast cancer her3+ negative | MNDR-E-MI-18129 |
| MNDR | hsa-miR-15a-5p | Low grade dysplastic nodule | MNDR-E-MI-18130 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ADAMTS5 | Homo sapiens | RR00042323 |
TOP